- In June 2021, Bayer AG announced a strategic acquisition of Noria Therapeutics Inc. and PSMA Therapeutics Inc., gaining exclusive rights to the companies' investigational compound. This acquisition is expected to significantly bolster Bayer's oncology portfolio, enabling the company to enhance its research and development capabilities in cancer treatments. By integrating these innovative assets, Bayer aims to address unmet medical needs in oncology and strengthen its market position
- In April 2021, Sanofi revealed its acquisition of Tidal Therapeutics, a pre-clinical biotech firm known for developing a cutting-edge mRNA-based research platform. This acquisition is poised to enhance Sanofi’s research capabilities across oncology, immunology, and other disease areas. By leveraging Tidal's technology, Sanofi aims to accelerate the development of novel therapies, thus reinforcing its commitment to advancing healthcare solutions and addressing various therapeutic challenges
